Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes
Marion G. Peters(Northwestern University), Oliver Lenz(Janssen (Belgium)), Carey Hwang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephanie Buchholz, Veronica Miller(University of California, Berkeley), Patricia Méndez, Luisa M. Stamm(Merck & Co., Inc., Rahway, NJ, USA (United States)), Man‐Fung Yuen(University of Hong Kong - Shenzhen Hospital), Eric Donaldson, Thomas Berg(Leipzig University of Applied Sciences), Mala K. Maini(California Institute of Technology), Mitchell Leus(University of California, Berkeley), Su Wang(Rutgers, The State University of New Jersey), Poonam Mishra, Pietro Lampertico(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), John Fry, Isabelle Lonjon‐Domanec(Janssen (Belgium)), Ed Gane(University of Auckland), Norah A. Terrault(University of Southern California)
Cited by 9
Related Papers
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
|Gastroenterology|2015|799
Evidence-Based Incorporation of Serum Sodium Concentration Into MELD
|Gastroenterology|2006|777